Research and Clinical Trials

We are dedicated to offering you the latest and most innovative cancer care. Our doctors and research team will match you to the trial that is right for you. They will also discuss the risks and benefits of participating in a particular trial. We collaborate with Dayton Clinical Oncology Program as well as offering the following trials to bring research right here… close to home.

We are currently enrolling for the following trials:

Prostate Cancer:
Lantheus Study -NCT05712473
A Prospective Observational Multicenter Real-World Registry Assessing the Impact of the use of PYLARIFY PET in Patients with Newly Diagnosed and Recurrent Prostate Cancer

GPS Pro-CDI Trial (No NCT #)
Impact of the GPS on shared decision-making of patients with VLR, LR, FIR, UFIR, and HR prostate cancer.

Hemolytic Disorders:
Immune thrombocytopenia (ITP) – CVAY736I12301 NCT05653349
Phase 3 double – blind study of ianalumab verses placebo in addition to first – line corticosteroids in primary immune thrombocytopenia

2^nd Line Warm Autoimmune hemolytic anemia CVAY736O12301 NCT05648968
Phase 3 Double blind. Assess efficacy and safety of ianalumab verses placebo in Warm Autoimmune   hemolytic anemia pts who failed at least one line of tx.

Breast Cancer:
Opera-01 OP-1250-301 - NCT06016738
Phase 3 Open label study of OP-1250 monotherapy vs Standard of care of treatment of ER+, HER2- Advanced or Metastatic Breast Cancer following endocrine and CDK 4/6 Inhibitor Therapy

Prostate Cancer:
Curium Solar – NCT06235151 
A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection

Bladder Cancer:
Non-muscle invasive Bladder Cancer (Quilt 2.005) NCT02138734
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer

High Risk Non-Muscle Invasive Bladder Cancer (MoonRise-3) NCT06919965
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)

Lung and Breast Cancer:
Ovation 23-001-  Breast and Lung Cancer NCT06369441
Collection of Biological Specimens and Associated Health Information for Secondary Research in Future Studies
Breast and NSCLC